Medications in Single-Dose Vials: Implications of Discarded Drugs (2021)
Chapter: Appendix C: Stakeholder Input
Appendix C
Stakeholder Input
CORINNE AXELROD, Centers for Medicare & Medicaid Services
PETER BACH, Memorial Sloan Kettering Cancer Center
ALEXANDER BASTIAN, Value and Market Access Galapagos NV
CORBIN BENNETT, Kaiser Permanente
DONALD BERWICK, Institute for Healthcare Improvement
AMITABH CHANDRA, Harvard Kennedy School of Government
JACQUELINE CORRIGAN-CURAY, Office of Medical Policy, Center for Drug Evaluation and Research
JAY CROSSON, Kaiser Permanente
GWEN DARIEN, Patient Advocate Foundation
STACEY DUSETZINA, Vanderbilt University Medical Center
MICHAEL GANIO, ASHP Office of Practice Advancement
PETER GILBAR, University of Queensland
SHERRY GLIED, New York University
KEDAR GOKHALE, Janssen Research & Development Biotherapeutics on behalf of BioPhorum Fill Finish Group
DANIEL GOLDSTEIN, Petach Tkvah
MIREILLE JACOBSON, Center for Health Policy and Economics
RONALD KHOURY, U.S. Department of Defense
SARA LEVIN, House Committee on Ways and Means
PRABATH MALLUWA-WADU, Centers for Medicare & Medicaid Services
RICHARD L. SCILSKY, American Society of Clinical Oncology
MICHAEL SEIDEN, The US Oncology Network
BRIAN SERUMAGA, United States Pharmacopeia
SARAH SHIREY-LOSSO, Centers for Medicare & Medicaid Services
The committee also received written comments on the study from Cigna and BioPhorum. The comments are available in the public access file of the Committee on Implications of Discarded Weight-Based Drugs.
